5C3T
 
 | |
5ACM
 | | Mcg immunoglobulin variable domain with methylene blue | | 分子名称: | 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM, GLYCEROL, MCG, ... | | 著者 | Brumshtein, B, Esswein, S.R, Salwinski, L, Phillips, M.L, Ly, A.T, Cascio, D, Sawaya, M.R, Eisenberg, D.S. | | 登録日 | 2015-08-17 | | 公開日 | 2015-12-02 | | 最終更新日 | 2024-01-10 | | 実験手法 | X-RAY DIFFRACTION (1.05 Å) | | 主引用文献 | Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain.
Elife, 4, 2015
|
|
5A2I
 | | Crystal structure of scFv-SM3 in complex with APD-SGalNAc-RP | | 分子名称: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-alpha-D-galactopyranose, ANTIGEN TN, ... | | 著者 | Martinez-Saez, N, Castro-Lopez, J, Valero-Gonzalez, J, Madariaga, D, Companon, I, Somovilla, V.J, Salvado, M, Asensio, J.L, Jimenez-Barbero, J, Avenoza, A, Busto, J.H, Bernardes, G.J.L, Peregrina, J.M, Hurtado-Guerrero, R, Corzana, F. | | 登録日 | 2015-05-20 | | 公開日 | 2015-06-03 | | 最終更新日 | 2024-01-10 | | 実験手法 | X-RAY DIFFRACTION (1.88 Å) | | 主引用文献 | Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an Anti-Muc1 Antibody.
Angew.Chem.Int.Ed.Engl., 54, 2015
|
|
7CU5
 | | N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Programmed cell death protein 1, ... | | 著者 | Liu, K.F, Tan, S.G, Jin, W.J, Guan, J.W, Wang, W.L, Sun, H, Qi, J.X, Yan, J.H, Chai, Y, Wang, Z.F, Chu, X.D, Gao, G.F. | | 登録日 | 2020-08-21 | | 公開日 | 2020-10-14 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.81 Å) | | 主引用文献 | N-glycosylation of PD-1 promotes binding of camrelizumab.
Embo Rep., 21, 2020
|
|
5B8C
 | | High resolution structure of the human PD-1 in complex with pembrolizumab Fv | | 分子名称: | Pembrolizumab heavy chain variable region (PemVH), Pembrolizumab light chain variable region (PemVL), Programmed cell death protein 1 | | 著者 | Horita, S, Shimamura, T, Iwata, S, Nomura, N. | | 登録日 | 2016-06-14 | | 公開日 | 2016-10-26 | | 最終更新日 | 2023-11-08 | | 実験手法 | X-RAY DIFFRACTION (2.146 Å) | | 主引用文献 | High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Sci Rep, 6, 2016
|
|
5AYQ
 | |
5ACL
 | | Mcg immunoglobulin variable domain with sulfasalazine | | 分子名称: | 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID, MCG, SULFATE ION | | 著者 | Brumshtein, B, Esswein, S.R, Salwinski, L, Phillips, M.L, Ly, A.T, Cascio, D, Sawaya, M.R, Eisenberg, D.S. | | 登録日 | 2015-08-17 | | 公開日 | 2015-12-02 | | 最終更新日 | 2024-01-10 | | 実験手法 | X-RAY DIFFRACTION (1.49 Å) | | 主引用文献 | Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain.
Elife, 4, 2015
|
|
7C88
 | | Complex structure of JS003 and PD-L1 | | 分子名称: | JS003 Heavy chain, JS003 Light chain, Programmed cell death 1 ligand 1 | | 著者 | Bi, X, Shi, R, Chai, Y, Qi, J, Yan, J, Tan, S. | | 登録日 | 2020-05-29 | | 公開日 | 2021-04-14 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.997 Å) | | 主引用文献 | Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Signal Transduct Target Ther, 5, 2020
|
|
7CGW
 | | Complex structure of PD-1 and tislelizumab Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of tislelizumab Fab, Light chain of tislelizumab Fab, ... | | 著者 | Hong, Y, Feng, Y.C, Liu, Y. | | 登録日 | 2020-07-02 | | 公開日 | 2021-04-07 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (3.2 Å) | | 主引用文献 | Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
Febs Open Bio, 11, 2021
|
|
7ELX
 | |
7E9B
 | |
5D4K
 | |
1DLF
 | | HIGH RESOLUTION CRYSTAL STRUCTURE OF THE FV FRAGMENT FROM AN ANTI-DANSYL SWITCH VARIANT ANTIBODY IGG2A(S) CRYSTALLIZED AT PH 5.25 | | 分子名称: | ANTI-DANSYL IMMUNOGLOBULIN IGG2A(S), SULFATE ION | | 著者 | Nakasako, M, Takahashi, H, Shimada, I, Arata, Y. | | 登録日 | 1998-07-14 | | 公開日 | 1999-07-26 | | 最終更新日 | 2023-08-09 | | 実験手法 | X-RAY DIFFRACTION (1.45 Å) | | 主引用文献 | The pH-dependent structural variation of complementarity-determining region H3 in the crystal structures of the Fv fragment from an anti-dansyl monoclonal antibody.
J.Mol.Biol., 291, 1999
|
|
1EEU
 | | M4L/Y(27D)D/Q89D/T94H mutant of LEN | | 分子名称: | ISOPROPYL ALCOHOL, KAPPA-4 IMMUNOGLOBULIN (LIGHT CHAIN) | | 著者 | Pokkuluri, P.R, Cai, X, Gu, M, Stevens, F.J, Schiffer, M. | | 登録日 | 2000-02-03 | | 公開日 | 2001-02-03 | | 最終更新日 | 2023-08-09 | | 実験手法 | X-RAY DIFFRACTION (1.6 Å) | | 主引用文献 | Factors contributing to decreased protein stability when aspartic acid residues are in beta-sheet regions.
Protein Sci., 11, 2002
|
|
1EFQ
 | | Q38D mutant of LEN | | 分子名称: | KAPPA-4 IMMUNOGLOBULIN (LIGHT CHAIN), URANYL (VI) ION, ZINC ION | | 著者 | Pokkuluri, P.R, Cai, X, Gu, M, Stevens, F.J, Schiffer, M. | | 登録日 | 2000-02-09 | | 公開日 | 2001-02-09 | | 最終更新日 | 2021-11-03 | | 実験手法 | X-RAY DIFFRACTION (1.6 Å) | | 主引用文献 | Factors contributing to decreased protein stability when aspartic acid residues are in beta-sheet regions.
Protein Sci., 11, 2002
|
|
1EEQ
 | | M4L/Y(27D)D/T94H Mutant of LEN | | 分子名称: | KAPPA-4 IMMUNOGLOBULIN (LIGHT CHAIN) | | 著者 | Pokkuluri, P.R, Raffen, R, Dieckman, L, Boogaard, C, Stevens, F.J, Schiffer, M. | | 登録日 | 2000-02-01 | | 公開日 | 2001-02-01 | | 最終更新日 | 2023-08-09 | | 実験手法 | X-RAY DIFFRACTION (1.5 Å) | | 主引用文献 | Increasing protein stability by polar surface residues: domain-wide consequences of interactions within a loop.
Biophys.J., 82, 2002
|
|
7VUN
 | | Design, modification, evaluation and cocrystal studies of novel phthalimides regulating PD-1/PD-L1 interaction | | 分子名称: | (2~{S},3~{S})-2-[[6-[(3-cyanophenyl)methoxy]-2-(2-methyl-3-phenyl-phenyl)-1,3-bis(oxidanylidene)isoindol-5-yl]methylamino]-3-oxidanyl-butanoic acid, Programmed cell death 1 ligand 1 | | 著者 | Cheng, Y, Sun, C.L, Chen, M.R, Yang, P, Xiao, Y.B. | | 登録日 | 2021-11-03 | | 公開日 | 2022-09-14 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.701 Å) | | 主引用文献 | Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents.
Acta Pharm Sin B, 12, 2022
|
|
1EAJ
 | |
1DCL
 | |
1DVF
 | | IDIOTOPIC ANTIBODY D1.3 FV FRAGMENT-ANTIIDIOTOPIC ANTIBODY E5.2 FV FRAGMENT COMPLEX | | 分子名称: | FV D1.3, FV E5.2, ZINC ION | | 著者 | Braden, B.C, Fields, B.A, Ysern, X, Dall'Acqua, W, Goldbaum, F.A, Poljak, R.J, Mariuzza, R.A. | | 登録日 | 1996-04-13 | | 公開日 | 1996-08-17 | | 最終更新日 | 2024-06-05 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Crystal structure of an Fv-Fv idiotope-anti-idiotope complex at 1.9 A resolution.
J.Mol.Biol., 264, 1996
|
|
1CFV
 | |
7WVM
 | | The complex structure of PD-1 and cemiplimab | | 分子名称: | Heavy Chain of Cemiplimab, Light Chain of Cemiplimab, Programmed cell death protein 1 | | 著者 | Lu, D, Xu, Z.P, Liu, K.F, Tan, S.G, Gao, G.F, Chai, Y. | | 登録日 | 2022-02-10 | | 公開日 | 2022-04-20 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3.4 Å) | | 主引用文献 | PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
Front Immunol, 13, 2022
|
|
7VYT
 | | Crystal structure of human TIGIT(23-129) in complex with the scFv fragment of anti-TIGIT antibody MG1131 | | 分子名称: | CITRATE ANION, MG1131 heavy chain variable region, MG1131 light chain variable region, ... | | 著者 | Jeong, B.-S, Nam, H, Kim, M, Oh, B.-H. | | 登録日 | 2021-11-15 | | 公開日 | 2022-03-02 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.53 Å) | | 主引用文献 | Structural and functional characterization of a monoclonal antibody blocking TIGIT.
Mabs, 14, 2022
|
|
1DL7
 | |
7UVF
 | | Crystal structure of ZED8 Fab complex with CD8 alpha | | 分子名称: | CHLORIDE ION, GLYCEROL, Immunoglobulin heavy chain, ... | | 著者 | Yu, C, Davies, C, Koerber, J.T, Williams, S. | | 登録日 | 2022-05-01 | | 公開日 | 2022-10-12 | | 最終更新日 | 2024-04-03 | | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | | 主引用文献 | Preclinical development of ZED8, an 89 Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Eur J Nucl Med Mol Imaging, 50, 2023
|
|
